Tezcat Biosciences is committed to the research and development of novel biologic-based therapies to treat the most aggressive cancers. The first-generation technology has been optimized for tumor-specific killing, solid tumor penetration, and manufacturability. Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. Tezcat Biosciences has participated in the 2018 Entrepreneurship Lab (ELab) Program, an initiative of NYC's Economic Development Corporation (NYCEDC), and the Texas Medical Center's Accelerator for Cancer Therapeutics (TMC-ACT).